Accutar Biotechnology, Inc.

Evommune will leverage Accutar's AI-empowered drug discovery platform for therapies targeting chronic inflammatory diseases PALO ALTO, Calif. and CRANBURY, N.J., Nov. 28, 2023 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, and Accutar Biotechnology Inc., a company focusing on artificial intelligence (AI)-empowered drug discovery, today announced a new strategic partnership focused on the discovery of novel small molecule drug candidates in chronic inflammatory diseases. The collaboration will leverage Accutar's proprietary AI platform as well as Evommune's expertise in the design and development of novel oral small molecule treatments against targets that are the root cause of chronic immune-mediated inflammatory diseases. Terms of the agreement will not be disclosed. "We are excited to partner with Accutar, a leader in accelerating drug discovery, as we work to identify and validate novel targets that could have a profound impact on chronic inflammatory diseases," said Jeegar Patel, Ph.D., Chief Scientific Officer of Evommune. "Accutar has a highly sophisticated hybrid approach of computational drug design and wet lab validation, and we plan to leverage this to overcome the limitations of traditional drug discovery methods on our targets of interest – allowing us to more efficiently design safe and efficacious therapies for complex chronic inflammatory diseases. Accutar is a team we know well, having collaborated with them on our current program targeting PKCθ, and we are thrilled to be expanding our partnership in a broader capacity." "Chronic inflammatory diseases represent the greatest threat to human health today, with nearly 60 percent of people in the U.S. alone suffering from at least one chronic condition," said Jie Fan, Ph.D., Chief Executive Officer of Accutar. "We look forward to partnering with Evommune, a company with in-depth understanding in inflammatory diseases and extensive expertise in clinical development. By combining Evommune's deep biological insights with our AI-empowered medicinal chemistry engine, and its application to the discovery and development of clinically differentiated medicine, we have great confidence we'll be able to develop the next generation of therapies for chronic inflammatory diseases." About Evommune, Inc. Evommune, Inc., a Palo Alto based biotech company, is creating game-changing science to treat immune-mediated inflammatory diseases by discovering, developing, and delivering therapies that address symptoms and halt progressive disease. For more information, please visit Evommune.com. About Accutar Biotechnology, Inc. Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines. To learn more about Accutar, please visit us at AccutarBio.com. Contact: Paul Laland 415.519.6610 Paul.laland@evommune.com Jiaqi Ren media@accutarbio.com

CRANBURY, N.J. & SHANGHAI--(BUSINESS WIRE)-- Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0176, an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity. “The initiation of this study marks the second program from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC0176 Phase 1 study in the US and the IND clearance by the China National Medical Products Administration (NMPA) last year,” said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. “Prostate cancer is one of the most common cancers among men in China, and the increase in its incidence and death ranks highest in China. We look forward to accelerating the development of AC0176 globally to bring transformative medicines to patients worldwide.” The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0176 treatment in Chinese patients with metastatic Castration Resistant Prostate Cancer (mCRPC). Additional information on this clinical trial can be found on (NCT05673109). About AC0176 AC0176 is an investigational orally bioavailable, chimeric degrader of androgen receptor (AR) for the potential treatment of prostate cancers. AR is a hormonal transcription factor, and plays important roles during prostate cancer onset and progression. In preclinical studies, AC0176 has demonstrated potent and selective AR protein degradation with broad coverage of AR mutants, favorable pharmacological properties, as well as promising anti-tumor activities in animal models. About Accutar Biotechnology, Inc. Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines. Be transformative. For patients. To learn more about Accutar, please visit us at .

DUBLIN, Jan. 5, 2023 /PRNewswire/ -- The "Investor Series: Opportunities in the Artificial Intelligence in Drug Discovery Market" report has been added to ResearchAndMarkets.com's offering. The discovery and identification of novel drug candidates is a time-intensive process, which is fraught with several challenges. One of the main concerns associated with the drug development process is the high attrition rate, which is often linked to the trial-and-error method adopted for lead identification. In this context, only a small percentage of pharmacological leads are eventually translated into potential candidates for clinical studies. Further, of these candidates, nearly 90% are unable to advance further in the development process. This, in turn, leads to a significant loss for drug developers, in terms of both resources and finances. Usually, a prescription drug requires at least 10 years to reach the market, and an average investment of over USD 2 billion. In addition, it is reported that the drug discovery phase accounts for about one-third of the aforementioned costs. In recent years, artificial intelligence (AI) has emerged as prominent tool, demonstrated to have the potential to address a number of existing challenges. As a result, players engaged in the pharmaceutical domain have started implementing AI based tools to better inform their drug discovery and development operations, using available chemical and biological data. Currently, a number of AI-based techniques, including machine learning, deep learning, supervised learning, unsupervised learning and natural language processing are being used across various stages of the drug development process. Specifically, AI-based solutions are being extensively used in combination with deep learning algorithms to produce actionable insights for target identification, hit generation, as well as lead optimization. Such solutions are anticipated to increase the overall R&D productivity and reduce clinical failure of product candidates. Moreover, estimates suggest that, in 2022, the adoption of AI-based solutions for drug discovery are likely to enable savings worth USD 8.57 billion, with market projections suggesting cost savings of USD more than 28 billion by 2035. Despite the fact that niche startups are spearheading the innovation in this domain, several big pharma players are also actively acquiring capabilities for these technologies. Numerous tech giants, such as Google, IBM and Microsoft, have either developed their proprietary products or are offering solutions through collaborations with other industry stakeholders; for instance Google's DeepMind and IBM Watson. Even though only a few of such AI-based platforms have gone public, developers have experienced considerable growth in share value as their respective platforms / product candidates progressed through the various stages of development. Taking into consideration both the historical and contemporary scenarios, we believe that the AI-based Drug Discovery Market presents lucrative investment opportunities for both short- and long-term investors. Scope of the Report The "Investor Series: Opportunities in the Artificial Intelligence in Drug Discovery Market (Focus on Need for AI-based Drug Discovery, Market Landscape of Key Players, Analysis of Product Offerings and Affiliated Value Propositions, Insights from Historical Funding Activity, Startup Health Indexing, Potential Venture Opportunities, Financial Analysis of Key Public Ventures, Market Forecast and Opportunity Analysis, Insights from Publicly Disclosed Investor Exits and Key Acquisition Targets)" report provides detailed information on the AI-based Drug Discovery Market, along with a focus on drug discovery platforms, service and technology providers. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data. The report features the following details: A qualitative and quantitative (wherever information was available) perspective on the current need for AI in the drug discovery domain. It presents details on the key applications of AI in drug discovery, along with information on the benefits of using such methodologies over conventional discovery approaches. Further, it highlights various challenges faced during various stages of drug discovery, and the opinions of representatives from key stakeholder companies involved in this domain. A detailed analysis of AI-based drug discovery focused companies that were established post 2005, featuring inputs on observed trends related to basic input parameters, such as year of establishment, location of headquarters, company size, and type of venture. A quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, which was informed via secondary research. An assessment of the various products and affiliated services, offered by the companies mentioned above, featuring analysis based on number and types of services / platforms, and an informed perspective on the value of the aforementioned offerings based on multiple relevant aspects, namely intellectual capital related value, value to end users, developer value, and others. A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in providing AI-based services and platforms for drug discovery, captured in this report. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analyses. A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key companies discussed in the report. Further, it features a list of the leading investors in AI in drug discovery market, based on their participation in financing activity in this industry segment. An elaborate review of the overall AI-based Drug Discovery Market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies within the market landscape dataset. A business risk analysis, focused on some of the major categories of risk that are usually discussed in the industry, namely operations-related risks, overall business-related risks, financial risks, product / technology associated risks, and social, economic, environmental and political risks. Case studies of instances where investors have exited various AI-based drug discovery-related ventures, offering insights on returns on investment made (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the AI-based Drug Discovery Market. A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers. Key Topics Covered: Excel Deliverables 1. KEY PLAYERS AND PRODUCTS DATASET 2. FUNDING AND INVESTMENT ANALYSIS 3. POTENTIAL INVESTMENT OPPORTUNITIES 4. FUNDAMENTAL AND TECHNICAL FINANCIAL ANALYSIS 5. BUSINESS RISK ANALYSIS 6. MARKET FORECAST AND OPPORTUNITY ANALYSIS 7. RETURNS ON INVESTMENT PowerPoint Deliverables 1. Context 2. Project Approach 3. Project Objectives 4. Executive Summary Section I: Need for AI-based Drug Discovery Market and Market Landscape 5. AI-BASED DRUG DISCOVERY MARKET 6. Market Landscape 7. Product Landscape and Company Health Indexing 8. Value Proposition Analysis 9. Company Competitiveness Analysis Section II Analysis of Investments 10. Funding and Investments Analysis Section III Financial Analysis and Assessment of Business Risks 11. Financial Analysis of Public Ventures 12. Business Risk Analysis Section IV Market Forecast and Opportunity Analysis 13. Market Forecast and Opportunity Analysis Section V Analysis of Returns on Investment, Key Acquisition Targets and Promising Investment Opportunities 14. Analysis of Returns on Investment 15. Key Acquisition Targets 16. Promising Investments Analysis 17. Conclusion 18. Appendices Selection of Companies Mentioned 3BIGS 99andBeyond A2A Pharmaceuticals A2i Therapeutics AbCellera Absci Accutar Biotech Acellera AcuraStem Adagene Aganitha AI Therapeutics AI VIVO Ai-biopharma Aiforia Aigenpulse Ainnocence Alphanosos Anagenex Anima Biotech Antiverse ApexQubit Aqemia Arctoris Ardigen Aria Pharmaceuticals Arpeggio Biosciences Arzeda Atavistik Bio Atomwise Auransa BenevolentAI BERG BigHat Biosciences BioAge Labs Biolojic Design Biorelate BioSymetrics bioSyntagma biotx.ai CardiaTec Biosciences Causaly Cellarity Celsius Therapeutics CHARM Therapeutics ChemAlive ChemPass Cloud Pharmaceuticals Collaborations Pharmaceuticals Collective Scientific Cortex Discovery Cyclica CytoReason Data2Discovery Data4Cure Deargen Deep Genomics DeepMatter DeepCure Deepflare DeepTrait Denovicon Therapeutics DevsHealth DEXSTR Differentiated Therapeutics Dyno Therapeutics And More For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets